Toronto, Jan. 17, 2023 (GLOBE NEWSWIRE) — Diabetes Canada is proud to announce the winners of our End Diabetes Awards research competition. Each of the winning research projects has the potential to unlock new insights and breakthroughs in the field of diabetes management, care, and risk-reduction. These investigator-driven projects span biomedical, clinical, health services and population health research—and all aim to dramatically improve the lives of people living with type 1 and type 2 diabetes.
“Canada has a well-earned reputation for innovation in diabetes treatment and care that has dramatically improved the quality of life for people with diabetes,” says Laura Syron, President and CEO of Diabetes Canada. “Diabetes Canada is excited to invest in these researchers and their teams as they work to advance new discoveries and the next big breakthrough in diabetes care.”
From a project that is probing into the systemic health inequities that prevent high-risk communities from accessing life-saving technologies to a study that is exploring the possibility of delaying type 1 diabetes by resetting the immune system, these research projects are uncovering new and pioneering ways to tackle the growing burden of diabetes in Canada.
To end diabetes, we need to harness the transformative and combined power of technological, medical, and scientific research. That is why Diabetes Canada has committed $9 million in funds to the research community, ensuring that each of these 30 promising projects receive a $100,000 grant annually for three years.
The winning projects were rigorously evaluated by scientists with expertise in diabetes research, with input from people with lived experience, as well as our National Research Council.
“The diversity and strength of diabetes research in Canada can’t be overstated,” says Dr. Rob Screaton, Co-Chair of Diabetes Canada’s National Research Council. “These new awards will energize the dynamic research community and add to the growing excitement about identifying new treatments for people living with diabetes on the immediate horizon.”
“On behalf of Diabetes Canada and the millions of people in Canada currently living with diabetes, including myself, I would like to recognize the support of our incredible community of donors, without which this research funding would simply not be possible,” says Laura Syron.
Diabetes Canada currently supports 55 research projects from 15 research institutions and labs located across the country.
 
About Diabetes Canada
A world free of the effects of diabetes is our vision. That’s why we’re working together to improve the quality of life of people living with diabetes. We’re sharing knowledge and creating connections for individuals and the health-care professionals who care for them; advocating through public policy; and funding research to improve treatments and find a cure to end diabetes.
 

A common virus that can cause severe illness in older adults and young children, RSV cases were particularly widespread in the U.S. this fall.
Federal health agencies are investigating whether there is a link between BioNTech and Pfizer’s bivalent COVID-19 booster and stroke in seniors.
A cutting-edge cancer treatment from the drugmaker was recently approved in Japan to treat a type of lymphoma.
Edesa Biotech Inc (NASDAQ: EDSA) announced preliminary topline results from a Phase 2b study evaluating multiple concentrations of the company's drug candidate, EB01, as monotherapy for moderate-to-severe chronic Allergic Contact Dermatitis. EB01 is a non-steroidal anti-inflamamatory compound that inhibits secretory phospholipase 2. Edesa reported that 1.0% EB01 cream demonstrated statistically significant improvement over the placebo. For the primary endpoint, patients with 1.0% EB01-treated le
The company said its RSV vaccine was 83.7% effective against lower-respiratory diseases caused by RSV in the study.
Temple Health said the insurer "doesn't seem to understand how health care is provided in Philadelphia."
Is Pfizer stock a buy or a sell after getting a downgrade on its falling Covid-tied sales? Is PFE stock a buy or a sell right now?
"It sneaks up on them and then it becomes too late," one doctor said.
Carbon Health CEO Eren Bali speaks with Yahoo Finance’s Anjalee Khemlani about the health technology platform, doubling down on primary care, health care quality, and different business models in the industry.
Eating just one serving of freshwater fish each year could have the same effect as drinking water heavily polluted with “forever chemicals” for an entire month, a new study finds. The equivalent monthlong amount of water would be contaminated at levels 2,400 times greater than what’s recommended by the Environmental Protection Agency’s (EPA) drinking water…
"What's driving the category are demographics, aging of the population, as well as [an] increase in diabetes and diabetic eye disease," Regeneron CEO Len Schleifer said during the 41st annual J.P. Morgan Healthcare Conference in San Francisco.
Rising costs amid inflationary pressures are trimming margins for the Zacks Medical-Hospital industry players. Yet, HCA Healthcare (HCA), Universal Health (UHS), Acadia Healthcare (ACHC) and Tenet Healthcare (THC) are poised to win big with improving volumes.
“I just don’t feel good,” Tammy Slaton said in PEOPLE’s exclusive look at the season premiere of 1000-Lb. Sisters
By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT January 2023 Operational Update Lexaria Bioscience Corporation’s (NASDAQ:LEXX) CEO, Chris Bunka, published a shareholder letter last week highlighting 2022 achievements and outlining the expected path forward for its portfolio of programs. Mr. Bunka listed capital expenditure priorities, summarized successful results from
AXIM® Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance
Hong Kong customs officials seized over the weekend thousands of contraband antivirals headed for the mainland.
A particular change in the spike protein means the virus is spreading faster than ever
Many of us may have stored some extra at-home COVID-19 tests in case it is needed in the future but what should be done if the testing kit surpasses its expiration date?
Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.
To help your kidney health, avoid consuming too much sodium, potassium and phosphorous.

source

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *